

Special Issue

Oncology: State-of-the-Art Research and Initiatives in Japan

Message from the Guest Editors

In recent years, there has been great progress in the treatment of cancer, especially in pharmacotherapy, and the prognosis of patients with many types of cancer has dramatically improved. Many studies originating in Japan have contributed greatly to its progress, and there are many original studies and initiatives underway today that are precise and sensitive enough to be uniquely Japanese to be proud of in the world. In this Special Issue, we call for original research articles and review articles on high-quality basic research and clinical research originating from Japan. Moreover, we also welcome articles on research and initiatives related to cancer patient support and survivorship, which are becoming increasingly important in the era of long-term survival.

Guest Editors

Dr. Satoshi Ikeda

Department of Thoracic Oncology, Kansai Medical University, 2-5-1 Shin-machi, Hirakata 573-1010, Japan

Dr. Tateaki Naito

The Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan

Deadline for manuscript submissions

closed (31 December 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/151534

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)